Chapter 13 Early Onset Dementia

Fadil, Halim; Borazanci, Aimee; Haddou, E. Aït Ben; Yahyaoui, M.; Korniychuk, Elena; Jaffe, Stephen L.; Minagar, Alireza

doi:10.1016/s0074-7742(09)00413-9

Cited by 27 publications

(22 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Early-onset dementia (EOD) is defined as functionally impairing cognitive decline arising before the age of 65 years [1]. Aetiologies are diverse; although the most common presentations are secondary to Alzheimer's disease (AD) and frontotemporal dementia.…”

Section: Introductionmentioning

confidence: 99%

The Utility of the Addenbrooke's Cognitive Examination Version Three in Early-Onset Dementia

Elamin

Holloway

Bak

et al. 2015

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Background/Aims: Early-onset dementia (EOD) is defined as functionally relevant cognitive decline with age of onset at less than 65 years. The aim of this study was to investigate the utility of the recently validated third version of the Addenbrooke's Cognitive Examination (ACE-III) in predicting dementia diagnoses in EOD. Methods: ACE-III scores of EOD patients were compared to those of healthy controls (HC) and individuals with subjective memory impairment (SMI). Results: The study included 71 EOD patients (Alzheimer's disease, n = 31; primary progressive aphasia, n = 11; behavioural-variant frontotemporal dementia, n = 18, and posterior cortical atrophy, n = 11); there were 28 HC and 15 individuals with SMI. At a cut-off score of 88/100, the ACE-III displayed high sensitivity and specificity in distinguishing EOD from HC (91.5 and 96.4%) and SMI (91.5 and 86.7%). Conclusions: The ACE-III is a reliable cognitive screening tool in EOD.

show abstract

Section: Introductionmentioning

confidence: 99%

The Utility of the Addenbrooke's Cognitive Examination Version Three in Early-Onset Dementia

Elamin

Holloway

Bak

et al. 2015

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

show abstract

“…De nøler gjerne med å henvise videre til riktig instans, for eksempel hukommelsesklinikk (35). I en norsk studie med 69 demenspasienter under 65 år tok det i gjennomsnitt 59,2 måneder fra de første symptomene dukket opp til diagnosen frontotemporal demens ble satt, mens det tok 39,1 måneder å sette diagnosen Alzheimers demens (36).…”

Section: Utredning Tar Tidunclassified

Når demens rammer unge

Rosness¹,

Haugen²,

Engedal³

2011

Tidsskriftet

View full text Add to dashboard Cite

“…Dementia is characterized by loss of intellectual ability leading to disruption of multiple higher cortical functions including memory, reasoning, orientation, learning capacity, and emotional stability. [8,9] Progressive dementia is associated with Alzheimer's disease, which is a progressive neurodegenerative disorder associated with loss of neurons and is characterized by the presence of excessive amounts of neuritic plaques containing amyloid β protein and abnormal tau protein filaments in the form of neurofibrillary tangles. [10][11][12] Degeneration of cholinergic neurons, particularly in the basal forebrain, has been found to be associated with loss of the neurotransmitter acetylcholine.…”

Section: Introductionmentioning

confidence: 99%

Scopolamine induced behavioral and biochemical modifications and protective effect of Celastrus paniculatous and Angelica glauca in rats

Puri

Srivastava

Pandey

et al. 2014

Int J Nutr Pharmacol Neurol Dis

View full text Add to dashboard Cite

Introduction: Nootropic agents, including cholinesterase inhibitors are being used to improve memory, mood and behavior, but the side-effects associated with these agents have made their use limited. The present study has therefore been undertaken to assess the synergistic effects of Celastrus paniculatous and Angelica glauca on scopolamine induced dementia in rats. Materials and Methods: Rats were treated with scopolamine (1 mg/kg body weight, i.p.) alone and with donepezil (2 mg/kg body weight p.o.), C. paniculatous (150 mg/kg body weight, p.o) and A. glauca (150 mg/kg body weight, p.o.). The changes in behavioral and biochemical parameters were assessed in rats. Results: Scopolamine treated rats showed impaired learning and memory, increased activity of acetylcholinesterase (AChE) (50%), lipid peroxidation (60%), protein carbonyls (47%) and decreased levels of reduced glutathione (GSH) (35%), activity of superoxide dismutase (34%) and catalase (42%) in hippocampus as compared with control. Simultaneous treatment of C. paniculatous and A. glauca with scopolamine also caused an improvement in the learning and memory activity associated with AChE activity in hippocampus of rats as compared to those treated with scopolamine alone. Combined treatment of C. paniculatous, A. glauca and scopolamine significantly improved the learning and memory function and AChE activity (50%) associated with decreased lipid peroxidation (33%), protein carbonyls (27%) and increased levels of antioxidant enzymes like reduced GSH (46%), activity of superoxide dismutase (50%) and catalase (62%) in hippocampus of rats as compared with those treated with scopolamine alone. Conclusion: The results of the present study exhibit protective efficacy of combined treatment of C. paniculatous and A. glauca in scopolamine induced dementiaand promising as a memory enhancing agents that is associated with its strong antioxidant potential.

show abstract

Chapter 13 Early Onset Dementia

Cited by 27 publications

References 23 publications

The Utility of the Addenbrooke's Cognitive Examination Version Three in Early-Onset Dementia

The Utility of the Addenbrooke's Cognitive Examination Version Three in Early-Onset Dementia

Når demens rammer unge

Scopolamine induced behavioral and biochemical modifications and protective effect of Celastrus paniculatous and Angelica glauca in rats

Contact Info

Product

Resources

About